Findings from Teikyo University Provide New Insights into Breast Cancer (Paclitaxel and Vinblastine Increase Plasminogen Activator Inhibitor-1 Production In Human Breast Cancer Mcf-7 Cells but Not Mda-mb-231 Cells).

A recent study conducted by researchers at Teikyo University in Tokyo, Japan, has found that certain chemotherapy drugs used to treat luminal A-type breast cancer may increase the risk of thrombosis. The study focused on the production of plasminogen activator inhibitor-1 (PAI-1), a molecule that inhibits the fibrinolytic system and increases the risk of thrombosis. The researchers discovered that treatment with microtubule-associated anticancer drugs, such as paclitaxel and vinblastine, increased PAI-1 release from MCF-7 cells, a luminal A-type breast cancer cell line. However, this increase in PAI-1 production was not observed in MDA-MB-231 cells. These findings suggest that chemotherapy using microtubule-associated drugs may contribute to thrombosis in luminal A-type breast cancer patients. [Extracted from the article]